Douglas Pharmaceuticals hail ‘breakthrough’ in finding drug for treatmentresistant depression

+Print Archive
News

Douglas Pharmaceuticals hail ‘breakthrough’ in finding drug for treatmentresistant depression

Jonathan
Chilton-Towle
Douglas Pharmaceuticals chief science officer Peter Surman
Douglas Pharmaceuticals chief science officer Peter Surman says a recent trial of extendedrelease ketamine as a treatment for depression is showing promising early results
Douglas Pharmaceuticals is heralding early results of its trial on using ketamine to treat depression as possibly the most significant step in the fie